Perkins Coie Trust Co Lowers Stock Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Perkins Coie Trust Co lowered its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,748 shares of the exchange traded fund’s stock after selling 149 shares during the quarter. Perkins Coie Trust Co’s holdings in SPDR S&P Biotech ETF were worth $667,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. HBK Sorce Advisory LLC grew its holdings in shares of SPDR S&P Biotech ETF by 2.6% during the first quarter. HBK Sorce Advisory LLC now owns 4,538 shares of the exchange traded fund’s stock worth $431,000 after buying an additional 113 shares during the last quarter. Intellectus Partners LLC boosted its holdings in SPDR S&P Biotech ETF by 1.0% in the 2nd quarter. Intellectus Partners LLC now owns 11,334 shares of the exchange traded fund’s stock valued at $1,051,000 after purchasing an additional 113 shares in the last quarter. Pacific Center for Financial Services boosted its holdings in SPDR S&P Biotech ETF by 2.8% in the 1st quarter. Pacific Center for Financial Services now owns 4,359 shares of the exchange traded fund’s stock valued at $414,000 after purchasing an additional 118 shares in the last quarter. Kingsview Wealth Management LLC boosted its holdings in SPDR S&P Biotech ETF by 3.8% in the 1st quarter. Kingsview Wealth Management LLC now owns 3,495 shares of the exchange traded fund’s stock valued at $332,000 after purchasing an additional 127 shares in the last quarter. Finally, Bourgeon Capital Management LLC boosted its holdings in SPDR S&P Biotech ETF by 5.9% in the 2nd quarter. Bourgeon Capital Management LLC now owns 2,427 shares of the exchange traded fund’s stock valued at $225,000 after purchasing an additional 135 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

XBI traded down $0.67 during trading on Wednesday, reaching $96.43. The company’s stock had a trading volume of 1,129,256 shares, compared to its average volume of 9,563,567. SPDR S&P Biotech ETF has a 52-week low of $63.80 and a 52-week high of $103.52. The company’s fifty day moving average price is $98.60 and its 200-day moving average price is $94.09. The company has a market capitalization of $7.35 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.